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This tenth best practice review examines four series of common
primary care questions in laboratory medicine: (i) antenatal
testing in pregnant women; (ii) estimated glomerular filtration
rate calculation; (iii) safety testing for methotrexate; and (iv)
blood glucose measurement in diabetes. The review is
presented in question–answer format, referenced for each
question series. The recommendations represent a pre´cis of
guidance found using a standardised literature search of
national and international guidance notes, consensus
statements, health policy documents and evidence-based
medicine reviews, supplemented by Medline Embase searches
to identify relevant primary research documents. They are not
standards but form a guide to be set in the clinical context. Most
are consensus rather than evidence-based. They will be
updated periodically to take account of new information.
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T
his is the tenth in a planned series of reviews
to answer a number of questions which arise
in primary care use of pathology.
Each subject is introduced with a brief summary
of the type of information found and is handled
separately, with authorship attributed.
While the individual subjects are not related as
they cover the disciplines of clinical biochemistry,
microbiology, immunology, haematology and
cellular pathology, they are designed once com-
pleted to form a resource which will be indexed
and cover a wide range of the most common
primary care laboratory issues, to be made avail-
able to users.
Where the new United Kingdom General
Medical Services (GMS) contracts make specific
reference to a laboratory test, the indicator or
target is appended at the end of the answer.
ANTENATAL TESTS IN NORMAL
PREGNANCY (MFS, JBH AND PRC)
The recommendations for normal pregnancy given
in this article are based largely on the guideline
entitled ‘‘Antenatal care: routine care for the
healthy pregnant woman’’ published in October
2003,1 commissioned by the National Institute for
Health and Clinical Excellence (NICE) from the
National Collaborating Centre for Women’s and
Children’s Health.
The ethos of the current guideline is that
pregnancy is a normal physiological process. Any
interventions offered (including laboratory tests)
should have known benefits and be acceptable to
pregnant women.
The guideline also stresses the importance of
communicating the purpose of tests and informing
women of all results.
Some women will require additional care
because of pre-existing medical conditions or risk
factors for complicated pregnancy (see box 1). This
article does not address how to identify or manage
these individuals. The merits of screening normal,
healthy women for a number of conditions are not
clearly established and this article highlights some
areas where uncertainty remains.
What tests should I perform on a newly
pregnant woman (first and subsequent
pregnancies)?
We recommend the following:
N Clinical biochemistry
– Down syndrome screening at the first
antenatal appointment
– Urinalysis for protein and blood and blood
pressure measurement at each antenatal visit
(10 appointments are recommended for a
nulliparous woman)
– No other biochemical tests are necessary
systematically
– Screening for plasma fasting glucose at
booking and 28 weeks in women identified
to be at higher risk of gestational diabetes
mellitus (GDM) (box 1)
– Systematic (universal) screening at 28 weeks
may be beneficial.
N Haematology. All the following tests should be
offered at the first antenatal appointment and if
accepted, arranged before 16 weeks of pregnancy:
– ABO blood group
– Rhesus D (RhD) status
– Atypical red cell alloantibodies
– Full blood count (FBC)
– Repeat screening for anaemia and atypical
antibodies (regardless of RhD status) should
be offered at 28 weeks
– Haemoglobinopathy screening (unless pre-
vious documented result).
N Microbiology/virology. All the following tests
should be offered at the first antenatal appoint-
ment and if accepted, arranged before 16 weeks
of pregnancy:
– Screening for rubella antibody, syphilis, HIV
and hepatitis B
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– Screening for asymptomatic bacteriuria
– Screening for group B streptococcus (GBS) is not
currently recommended in the UK
– Pregnant women should not be offered routine screening
for asymptomatic bacterial vaginosis or chlamydia infec-
tion
– Pregnant women should not be offered routine screening
for cytomegalovirus, toxoplasmosis or hepatitis C.
Biochemical tests
Down syndrome screening
This is offered and explained at the first antenatal visit. If
accepted, ultrasound assessment is carried out at 11–14 weeks
and serum testing 14–20 weeks. This will not be considered
further as it is the subject of individual national screening
policies and practices. New developments are being evaluated
in the UK, in particular, serum testing with different marker
combinations at an earlier stage in pregnancy (11–13 weeks).
The current UK policy position may be accessed at the NHS
Antenatal and Newborn Screening programme website
(www.screening.nhs.uk/downs/procedures.htm).
Urinalysis for proteinuria
Pre-eclampsia is a multi-system disorder affecting 2–10% of
pregnancies and results in increased maternal and neonatal
morbidity and mortality. It is defined as hypertension new to
pregnancy manifesting after 20 weeks of gestation associated
with a new onset of proteinuria, which resolves after delivery.
Hypertension new to pregnancy without proteinuria and
resolving after delivery is termed pregnancy-induced hyperten-
sion.
Reagent strip (dipstick) urinalysis is sufficient for initial
testing but is prone to observer error. Strips must be used
within the expiry date and according to manufacturers’
instructions. Automated reading devices significantly reduce
both false positive and false negative rates but add to the cost.2
An initial result of >1+ should be confirmed by laboratory
measurement of protein/creatinine ratio on a random urine
sample. A protein/creatinine ratio of 30 mg/mmol is regarded as
significant.3 4
Other biochemical tests
No other biochemical tests are necessary. In particular,
universal screening for gestational diabetes mellitus (GDM),
including dipstick testing for glycosuria, is not currently
recommended by either NICE1 or the UK National Screening
Committee5 because it meets only some of the well established
criteria for such a programme.6 This field is beset by uncertainty
over definitions, diagnostic tests and optimal clinical manage-
ment. The World Health Organization (WHO) defines GDM as
any degree of carbohydrate intolerance with onset or first
recognition in pregnancy, applying criteria from non-pregnant
subjects to identify ‘‘abnormal’’ blood or plasma glucose levels.
Unanswered questions remain:
N Is it appropriate to define an abnormality in pregnant
women using data from non-pregnant subjects when there is
a physiological increase in glucose levels in pregnancy?
N Does intervention improve outcomes for mother and baby at
all levels of abnormal glucose tolerance in pregnancy?
The Australian Carbohydrate Intolerance Study (ACHOIS)7
has reopened the debate in the UK as it provides evidence that
active intervention in women with relatively mild impairment
of glucose tolerance results in improved perinatal outcomes.
The Scottish SIGN guideline8 recommends screening in
pregnancy in urine at every antenatal visit. It recommends a
random venous plasma glucose if 2+ glycosuria is detected, and
routinely at 28 weeks gestation. It adds that the WHO advises
that a 75 g oral glucose tolerance test (OGTT) should be carried
out if the blood glucose is .5.5 mmol/l two hours or more after
food, or .7 mmol/l within two hours of food.
In addition the American Diabetes Association guidance9
recommends that testing may not be needed in women with no
risk factors for developing GDM, but testing all others.
Recent guideline development suggest that an approach of
screening routinely at 28 weeks with targeted screening of
higher risk patients (box 1) at booking or in the first trimester
may emerge (Professor R Bilous, personal communication, Feb
2007).
Further valuable data is expected from the Hyperglycaemia
and Adverse Pregnancy Outcome Study (HAPO).10 This is a large,
epidemiological study of a heterogeneous, ethnically diverse
cohort of 25 000 women designed to clarify the relationship
between adverse pregnancy outcomes and various levels of
glucose intolerance less severe than overt diabetes mellitus.
There is no consensus on which screening test would be most
appropriate for a universal programme and a variety of policies
currently prevail in UK obstetric practice.6 It is to be hoped that
a more coherent national approach can be recommended in the
anticipated update to NICE guidance which is due to be
published in 2007.
It should be noted that in practice urine protein dipstick tests
frequently also measure glucose and that this level of screening
facility is probably therefore in widespread use although is
insensitive compared to fasting plasma glucose or OGTT.
Haematological tests
ABO blood group, RhD status and atypical red cell
alloantibodies
This is to identify any possible transfusion problems which
might arise, anticipate the need for anti-D prophylaxis in RhD
negative women and to determine the risk of other types of
haemolytic disease of the newborn.
FBC
FBC will detect anaemia (low haemoglobin), but also less
commonly, white cell and platelet abnormalities. The normal
UK haemoglobin in pregnancy is accepted as >110 g/l at up to
12 weeks, and >105 g/l at 28–30 weeks. A significantly
abnormal result will dictate further investigations, for example
ferritin if haemoglobin and mean cell volume (MCV) are
reduced. Serum ferritin is the most sensitive single screening
test to detect adequate iron stores, with a sensitivity of 90% at a
cut-off of 30 mg/l.
Haemoglobinopathy (principally thalassaemia and
sickle cell anaemia)
An NHS Sickle Cell and Thalassaemia screening programme for
pregnant women commenced in April 2005.5 11 All pregnant
Box 1: Higher risk women who may justify
screening at booking or in first trimester
N Severe overweight (body mass index .30 kg/m2)
N Past history of poor pregnancy outcome
N First degree family history of diabetes
N Previous history of disorder of glucose metabolism
N High risk ethnic origin
N Possible, older women
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women in Trusts defined as high prevalence (sickle cell disease
expected to affect more than 1.5 per 10 000 pregnancies)
should be offered antenatal screening. Women in low pre-
valence Trusts (sickle cell disease expected in less than 1.5 per
10 000 pregnancies) should, from April 2006, be offered
screening based on family origin and formal inspection of
blood count indices.
Microbiological tests
Screening for rubella, syphilis, HIV and hepatitis B
Testing for rubella susceptibility identifies women at risk of
contracting infection and who need vaccination in the postnatal
period to protect future pregnancies. Although syphilis is
relatively rare in the UK, treatment as early as possible is
beneficial to mother and fetus. Antenatal intervention in HIV
positive women and postnatal intervention in hepatitis B
positive women reduces mother to child transmission. Tests
for all four of these infectious diseases can be carried out on a
single blood sample, and there are well-established pathways
for dealing with positive screening results of
serological tests
Screening for asymptomatic bacteriuria (first and
subsequent pregnancies)
All pregnant women should be offered routine screening for
asymptomatic bacteriuria by midstream urine culture at their
first antenatal visit. It may be helpful to repeat samples if
contamination is suspected. If, however, there is a pure or
predominant growth of 105 organisms per ml, the woman
should be treated with an appropriate antimicrobial agent.1 A
further urine culture should be performed as a test of cure and
again at regular intervals (monthly) for the remainder of
gestation.
The prevalence of asymptomatic bacteriuria in pregnancy is
about 5%, the same as in non-pregnant women. During
pregnancy there is a dilatation of the ureters and renal
pelvices with decreased ureteric peristalsis, changes beginning
as early as the seventh week of gestation.12 This predisposes
to infection, and about a third of pregnant women with
untreated bacteriuria develop acute pyelonephritis.13 Infec-
tion may also be complicated by low birth weight and
prematurity, pre-eclampsia, maternal anaemia, amnionitis
and intrauterine death.1 More controversial is whether screen-
ing is cost effective. This depends partly on the nature of
the population being screened (affluent populations have
a lower prevalence of bacteriuria). The two most widely
used strategies for diagnosing bacteriuria are the use of
leucocyte esterase-nitrite dipsticks and quantitative urine
culture. Urine culture is more expensive, but has a higher
sensitivity and specificity and is therefore the recommended
test.1 14
Based on the original work of Kass in 1957,15 bacteriuria has
traditionally been diagnosed on the basis of a pure or
predominant growth of 105 organisms (enterobacteria, ‘‘coli-
forms’’) per ml of a properly taken clean catch or midstream
specimen of urine.13 Kass recommended that positive cultures
should be repeated for confirmation on the basis that two
positive results increase the post-test probability of true
bacteriuria from 80% to 95%. However, workers have relied
on single samples,13 and NICE currently recommends treatment
based on the result of a single screening test.1
A midstream urine culture should be requested routinely at
first antenatal visit. A urine culture should be performed 7 days
after antibiotic treatment as a test of cure, and at regular
intervals (monthly) for the remainder of gestation, as women
whose bacteriuria fails to respond to treatment are at highest
risk of developing symptomatic infection.12
Screening for group B haemolytic streptococcus
(Streptococcus agalactiae)
Antenatal screening for group B Streptococcus (GBS) is not
currently recommended in the UK. Pregnant women with risk
factors for early-onset neonatal GBS disease may be offered
intrapartum chemoprophylaxis; therefore GBS cultured inci-
dentally from antenatal samples, including urine samples,
should be reported by the laboratory.
GBS is the most frequent cause of severe early-onset neonatal
infection in the UK, causing septicaemia, pneumonia and
meningitis. The incidence is estimated to be 0.5/1000 births and
approximately 10% of infections are fatal.1 16 GBS may also
cause maternal infections such as amnionitis, endometritis or
septicaemia. Risk factors for early-onset GBS disease are
intrapartum fever, prolonged rupture of membranes, delivery
at,37 weeks gestation and a previous infant with GBS disease.
GBS is carried asymptomatically by approximately 25% of
pregnant women in the UK. In the USA, where the incidence of
GBS disease was previously three times that in the UK,
interventions have been associated with a reduction in GBS
disease.17 In the USA, a universal culture-based screening
programme is used to detect GBS carriage, using both vaginal
and rectal swabs at 35–37 weeks gestation. Intrapartum
antimicrobial prophylaxis is given to GBS-colonised women
and those with risk factors for GBS disease, supported by the
use of algorithms.17 The effectiveness of screening in preventing
early-onset neonatal GBS disease has been estimated at 50–80%
based on observational studies.1 16 Since the introduction of
universal screening in the USA in the 1990s, the incidence of
early-onset GBS disease has fallen to a similar level to that seen
in the UK.
In the UK, NICE has recommended that women should not
be offered routine antenatal screening for GBS because
evidence for clinical and cost effectiveness remains uncertain.1
Box 2: Pregnant women who may need additional
care
N Conditions such as hypertension, cardiac or renal
disease, endocrine, psychiatric or haematological dis-
orders, epilepsy, diabetes, autoimmune diseases, cancer,
HIV
N Factors that make the woman vulnerable, such as lack of
social support
N Age >40 years or (18 years
N Body mass index greater >35 or ,18
N Previous caesarean section
N Severe pre-eclampsia, HELLP (haemolysis, elevated liver
enzymes, low platelets) or eclampsia
N Previous pre-eclampsia or eclampsia
N Three or more miscarriages
N Previous preterm birth or mid-trimester loss
N Previous psychiatric illness or puerperal psychosis
N Previous neonatal death or stillbirth
N Previous baby with congenital abnormality
N Previous small-for-gestational-age or large-for-gesta-
tional-age infant
N Family history of genetic disorder
Box 2 is adapted from the practice algorithm in NICE Clinical
Guideline 6.1
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Screening and prophylaxis strategies have not demonstrated an
overall effect on all-cause neonatal sepsis or neonatal mortal-
ity.16 However, since approximately 60% of early-onset GBS
cases have risk factors for GBS, the Royal College of
Obstetricians & Gynaecologists currently recommends that
pregnant women should be considered for intrapartum
prophylaxis on the basis of risk factors, rather than culture-
based screening.16
Screening for bacterial vaginosis
Bacterial vaginosis (BV) is the most common cause of vaginal
discharge and malodour. BV results from a change in the
normal flora of the vagina with a relative overgrowth of
anaerobic bacteria. The condition is not sexually transmitted,
but is associated with sexual activity. The presence of BV during
pregnancy is around 10–20%, and 50% of these women are
asymptomatic. BV is associated with pre-term birth: women
with BV are twice likely to deliver pre-term than women
without BV. There is no evidence that screening and treating
asymptomatic women who are not at high risk improves
outcomes such as pre-term labour or birth.1 18 Further studies
are required to define the role of screening and treating for BV
in pregnant women who have experienced previous pre-term
delivery, as treatment may reduce pre-term birth in these women.
Conclusion
In conclusion, a limited number of investigations are recom-
mended for a newly pregnant woman who is healthy (box 2).
These should be offered and explained at the first antenatal
visit.
GMS contract indicator: none.
CALCULATION OF ESTIMATED GLOMERULAR
FILTRATION RATE IN ADULTS (PJT)
This question considers the recommended method used to
calculate estimated glomerular filtration rate (eGFR) and
frequency of measurement in patients with chronic kidney
disease. Different methods are available in textbooks and on
the internet for rapid calculation of eGFR; they may, however,
produce different results and confuse serial interpretation of
renal function testing. The answers do not consider further
testing which may be appropriate in patients with chronic
kidney disease, for which the reader is referred to the joint
Renal Association/Royal College of Physicians 2005 guidance.19
How should I estimate glomerular fil tration rate?
We recommend:
N Using the MDRD 4 equation adjusted for laboratory method,
either as calculated by the laboratory performing the tests or
using the equation provided by that laboratory.
N Other calculations (particularly Cockcroft and Gault) will
not produce parallel results and should not be used to
classify CKD along current guidelines.
The principal function of the glomeruli is to filter water and
low molecular weight components of the blood while retaining
cells and high molecular weight components. The glomerular
filtration rate (GFR) is thus the rate at which substances are
filtered through the glomeruli and cannot be directly measured.
It plays an important role in the diagnosis and treatment of
chronic kidney disease (CKD) as it precedes clinical symptoms
in all forms of progressive kidney disease. It is thus a marker of
progression, and a predictor for the onset and complications of
renal disease. It must be noted that while eGFR is the pillar of
CKD diagnosis, staging and management it is only one
component of clinical assessment.
Gold standard methods for the assessment of GFR are
impractical for widespread use; creatinine is an insensitive
marker of CKD, while measured creatinine clearance using a
24 hour urine sample is unreliable. Formula based estimations
of glomerular filtration rate (eGFR) are more sensitive than
creatinine for detecting moderate CKD. Accordingly, the
National Service Framework (NSF) for Renal Services recom-
mended the use of eGFR20 in adults. Subsequently, the use of
the isotope dilution mass spectrometry (ID-MS) creatinine
traceable version of the four-variable modification of diet in
renal disease (MDRD) formula was recommended21 for the
estimation of glomerular filtration rate (eGFR) by clinical
biochemistry laboratories:
GFR (ml/min/1.73 m2) = 175 6 [serum creatinine
(mmol/l))/88.4]21.154 6 (age)20.203 6 [1.212 if black] 6
[0.742 if female]
This version differs from the initial four-variable MDRD
formula.22 If the patient is not Caucasian or African-Caribbean,
an assumption of Caucasian ethnicity can be made as there
currently is no evidence to suggest that eGFR is invalid in these
groups.21 If the ethnic origin of the patient is unknown, then
the patient should be assumed to be Caucasian until the
ethnicity is confirmed. While the equation has not been
validated for other ethnic groups or in those .70 years, eGFR
is still recommended as it is more accurate than serum
creatinine alone.
To improve inter-laboratory agreement, laboratories should
apply method specific correction factors in order to improve
alignment between creatinine assays.23 This takes into account
the slope and intercept of the method when compared to ID-
MS measured creatinine. It is important that such laboratories
utilise the assays as intended by their manufacturers.23 The
recommended method for laboratories to use is:
GFR (ml/min/1.73 m2) = 175 6 ((method-specific inter-
cept + [serum creatinine (mmol/l)]/slope)/88.4)21.154 6
(age)20.203 6 [1.212 if black] 6 [0.742 if female]
Box 3: Recommended antenatal tests: summary
N Laboratory tests to be arranged early in pregnancy
(before 16 weeks gestation)
– ABO blood group, rhesus D (RhD) status and atypical
red cell alloantibodies
– full blood count (to screen for anaemia)
– haemoglobinopathy (sickle cell and thalassaemia)
– hepatitis B surface antigen
– HIV 1/2 antibody
– rubella IgG antibody
– syphilis serology
– midstream urine culture for asymptomatic bacteriuria
– urinalysis for protein
– serum screening for Down syndrome at 14-20 weeks
N Laboratory tests to be repeated during pregnancy
– urinalysis for protein, along with blood pressure
measurement at each antenatal visit
– repeat full blood count and atypical red cell alloanti-
bodies at 28 weeks
Box 3 is adapted from the practice algorithm in NICE Clinical
Guideline 6.1
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It should be noted that eGFR is an estimate that assumes
that the patient is representative, for weight and height, of their
age, gender and race; accordingly, it should be employed in
conjunction with clinical judgement. In particular, it has not
been validated for use in patients with pregnancy, malnour-
ishment, amputations, muscle wasting disorders, oedematous
states and acute renal impairment. Situations of proportio-
nately low muscle bulk will tend to overestimate eGFR and
those of increased muscle mass to underestimate it. All adult
serum or plasma creatinine requests received by laboratories
should have eGFR reported, bearing in mind the above issues.23
The US National Kidney Foundation has derived five stages
of CKD based on eGFR (see table 1). CKD is defined as either
kidney damage or eGFR ,60 ml/min/1.73 m2 for >3 months,
with kidney damage being defined as pathological abnormal-
ities or markers of damage including abnormalities in blood,
urine or imaging tests. These conditions include persistent
microalbuminuria, persistent proteinuria, persistent haema-
turia (non-urological), renal structural abnormalities such as
polycystic kidney disease or reflux nephropathy, and biopsy-
proven chronic glomerulonephritis. Accordingly, eGFR values
>60 ml/min/1.73 m2 (stages 1 and 2) are normal unless other
evidence of kidney damage exists. Values of eGFR ,60 ml/min/
1.73 m2 must be confirmed after 3 months to classify the
patient as having CKD.
It should be noted that many pharmacy computations for
drug dosage adjustment are based on the e GFR calculated by
the Cockcroft and Gault equation, on which the original
computations were based. This produces different results and
is adjusted for body surface area. This is a current source of
potential confusion.
How often should I measure eGFR?
We recommend the following.
CKD stages 1–3
N At least 12 monthly if changing by,15% between successive
measurements.
N 6 monthly if changing by .15% between successive
measurements.
CKD stages 4 and 5
N At least 6 monthly if changing by ,15% between successive
measurements.
N At least 3 monthly if changing by .15% between successive
measurements.
Patients with CKD 3 should have a repeat eGFR at least every
12 months if eGFR is stable and 6 monthly if not.19 The
definition of stable is a relative eGFR change of ,15%24 over
6 months; for example, a change from 59 ml/min/1.73 m2 to
55 ml/min/1.73 m2 is a change of (59–55) 6 100/59 or 2.4%,
which is consistent with being stable, whereas a change from
59 ml/min/1.73 m2 to 49 ml/min/1.73 m2 is a change of (59–49)
6 100/59 or 16.9%, which is not consistent with being stable.
Patients with CKD 4 and 5 should have a repeat eGFR at least
every 6 months if eGFR is stable, and 3 monthly if not.19
Patients with eGFRs consistent with CKD 1 and 2 with
diabetes, vascular disease, heart failure, hypertension, urinary
tract obstruction, neurogenic bladder or surgical urinary
diversion, people taking diuretics, angiotensin converting
enzyme inhibitors or angiotensin II receptor blockers and
people with a family history or genetic risk of kidney disease
should have a repeat eGFR at least every 12 months.25
Independent of the individual clinical profile, what tests
should I carry out in addition to eGFR testing?
CKD stages 1–2
We do not recommend any additional tests.
CKD stage 3
Haemoglobin, serum cholesterol, potassium, calcium, phos-
phate and urine dipstick measurement for proteinuria (micro-
albuminuria in diabetic patients) are recommended annually. If
the urine dipstick for proteinuria is positive, laboratory
quantification of the protein creatinine ratio is advised.
Fasting plasma glucose is recommended every 5 years.
CKD stages 4 and 5
N Haemoglobin, serum potassium, calcium, and phosphate
measurement are recommended at least 6 monthly if eGFR
changes by ,15% between successive measurements.
N Haemoglobin, serum potassium, calcium and phosphate
measurement are recommended at least 3 monthly if eGFR
changes by .15% between successive measurements.
N Annual serum cholesterol and urine dipstick measurement
for proteinuria (microalbuminuria in diabetic patients) are
recommended. If the urine dipstick for proteinuria is
positive, laboratory quantification of the protein creatinine
ratio is advised.
N These patients will normally be under the (joint) care of a
nephrology service.
The majority of patients with CKD are at increased risk of
cardiovascular disease. However, independent of established
vascular disease, diabetes or hypertension, there is no agree-
ment whether such patients should receive primary or
secondary vascular prevention.
While a very small minority of patients with CKD progress to
end stage kidney disease, it is important to identify these
patients. Persistent proteinuria (protein:creatinine ratio
.100 mg/mmol) is the best indicator of this risk, although
microalbuminuria should be used in diabetic patients.
Clinically significant bone mineral disorders due to kidney
impairment are uncommon in people with stage 3 CKD.
Though biochemical abnormalities can develop, routine
requests for parathyroid hormone and vitamin D assays are
not recommended when inorganic phosphate is not elevated, or
the patient is in primary care.
Anaemia due to kidney disease is uncommon in stage 3 CKD,
except in those with diabetes mellitus or an eGFR of ,45 ml/
min/1.73 m2. All patients with anaemia should be investigated
for alternative causes before ascribing this to CKD.
GMS contract indicator: register of CKD patients stages 3–5.
SAFETY MONITORING IN THE USE OF LOW DOSE
METHOTREXATE (AMK, JPN)
This answer considers the monitoring recommended for
patients being treated in shared care, with specialist super-
vision, with low dose methotrexate for inflammatory disease
(rheumatoid arthritis, psoriasis). It does not apply to use in
Table 1 Stages of chronic kidney disease (CKD)
CKD
stage Description eGFR (ml/min/1.73 m2)
1 Normal or increased eGFR* >90
2 Mildly decreased eGFR* 60–89
3 Moderately decreased eGFR 30–59
4 Severely decreased eGFR 15–29
5 Kidney failure ,15 (or dialysis)
eGFR, estimated glomerular filtration rate.
*Normal unless other evidence of kidney damage exists.
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malignant disease and other occasional unlicensed indications,
for which individual guidance from the specialist concerned
should be observed. Serious incidents have occurred frequently
with methotrexate, a significant proportion of which derive
from failure to monitor according to guidelines or to act
appropriately on monitoring results.
What safety monitoring is required for methotrexate
used in non-malignant disease?
We recommend:
N Baseline full blood count (FBC), serum creatinine and liver
function tests (LFTs) before methotrexate therapy is
commenced.
N FBC, serum creatinine and LFTs should be monitored every
week until the dose of methotrexate is stable.
N Once the dose is stable, FBC, serum creatinine and LFTs
should be checked every 1–2 months.
N For patients taking methotrexate for psoriasis, monitoring of
serum amino-terminal peptide of type III procollagen
(PIIINP), a marker of hepatic fibrosis, is also recommended
if available, every 2–3 months.
The recommendations in this article refer to the use of
methotrexate in low dose as a disease-modifying agent as
opposed to its use in high dose as a chemotherapeutic agent.
Methotrexate is licensed for use in moderate to severe
rheumatoid arthritis and in severe recalcitrant psoriasis, which
is unresponsive to conventional therapy.26 It is unusual as it is
given only once weekly, either orally or parenterally. Common
side effects include nausea, diarrhoea, mucositis and abnormal
LFTs.27 The most serious toxicities are hepatic fibrosis and
cirrhosis, pneumonitis and myelosuppression.28 Weekly folic
acid treatment reduces the risk of gastrointestinal and mucosal
side effects.29
The National Patient Safety Agency (NPSA) reviewed 137
incidents related to oral methotrexate use in the UK.30 Eight out
of 25 reported deaths and 2 out of 26 incidents of serious harm,
requiring hospitalisation, were due to failure of monitoring
procedures, including: failure to perform regular blood tests,
delays in receiving results and failure to alter treatment after
receiving abnormal results. Despite the safety report, incidents
have continued to be reported to the NPSA.31
The incidence of cytopenia (neutropenia, thrombocytopenia
or pancytopenia) is not high, estimated at 1% in patients with
rheumatoid arthritis receiving low-dose methotrexate.32
However, this toxicity may be fatal in up to 15–20% of cases.32
Although the cytopenia can occur at any time during
treatment,32 neutropenia with low-dose methotrexate occurs
late with a median delay of around 16 months, which suggests
a cumulative dose effect as the likely mechanism.33 Earlier
onset or a more severe degree of myelosuppression can occur
and are thought to be due to elevated levels of methotrexate as
a result of renal impairment, drug interactions, hypoalbumi-
naemia and drug errors.32 34 However, severe pancytopenia can
occur suddenly, without warning signs and independent of
dose of methotrexate; this complication very likely represents
an idiosyncratic drug reaction.35
For practical reasons, the recommendation for monitoring
haematological toxicity of low-dose methotrexate therapy is to
check the blood counts prior to starting, then weekly until the
dose is stable and subsequently every 1–2 months. While such
monitoring will help clinicians to identify patients who have
developed subclinical or asymptomatic haematological toxicity,
it is important that patients are also well educated in
recognising symptoms or signs of cytopenia (eg, fever, sore
throat, bleeding) and seek urgent medical attention to have
their blood counts checked sooner than planned; this is because
cytopenia can occur in an unpredictable fashion in some groups
of patients.32 35
All the guidelines reviewed26 30 36–38 recommend pretreatment
assessment of renal function with serum urea, electrolytes and
creatinine. Methotrexate is concentrated in the kidney and 60–
95% of a dose is renally excreted. Therefore, methotrexate is
contraindicated in patients with significant renal impairment.39
Monitoring recommendations, during dose stabilisation, vary
from weekly26 38 to every two weeks.30 37 In the stable patient
opinion is divided as to the frequency of monitoring required,
from 4–6 weekly,28 37 2–3 monthly26 30 38 or 6–12 monthly.36
Abnormal renal function increases the risk of acute myelosup-
pression,38 so the dose of methotrexate should be reduced if
there is a significant deterioration in renal function.36 38
All the recently published guidelines agree that liver function
tests, including serum albumin and alanine aminotransferase
(ALT) or aspartate aminotransferase (AST), should be checked
before commencing methotrexate therapy. There is a lack of
consensus on the frequency of monitoring required. The
Committee on Safety of Medicines26 and the British
Association of Dermatologists38 recommend weekly LFTs until
the methotrexate dose is stable. Monitoring every two weeks,
during dose stabilisation, is recommended by the British
Society of Rheumatologists,34 the Royal College of Nurses37
and the NPSA.30 The recommended frequency of monitoring of
stable patients varies from monthly26 28 34 35 to two or three
monthly.24 36 The likelihood of finding a raised serum transa-
minase (ALT or AST) is several-fold higher in patients with
rheumatoid arthritis taking methotrexate, compared to those
taking placebo. There is only one published case of clinically
significant liver disease occurring in a patient monitored every
4–8 weeks, with appropriate methotrexate adjustment.39
Methotrexate therapy should not be commenced if baseline
LFTs are abnormal.26 Patients with serum transaminases
greater than twice the upper limit of normal or with an
unexplained fall in the serum albumin should be discussed
with the rheumatologist29 36 and consideration given to with-
holding treatment. Abnormal LFTs may be more common in
patients with psoriasis.40 41 The amino terminal peptide of type
III procollagen (PIIINP) is produced during the synthesis of
type III collagen. Serum PIIINP levels correlate with the degree
of hepatic fibrosis and are sensitive in detecting hepatic
fibrosis.42 Studies, in patient receiving long-term methotrexate
therapy for psoriasis, have shown that if PIIINP levels are
consistently normal, liver biopsy can be avoided.41 43 This
marker has been in routine use in the Greater Manchester
area in the UK since 1996.41 It is recommended that serum
PIIINP levels are checked in patients with psoriasis before
commencing methotrexate, and 2–3 monthly thereafter.36
Abnormal results should be discussed with the responsible
secondary care specialist. PIIINP is a recent marker and
recommendations on its use may change in coming years.
Methotrexate is a safe drug if monitored according to the
guidelines and the dose is adjusted accordingly.30 However for
safe prescribing, clarity is needed on the monitoring and
prescribing responsibilities between primary and secondary
care.44 The NPSA has produced a patient information leaflet
emphasising the importance of regular monitoring45 and a
patient-held blood monitoring and dosage record booklet.46
GMS contract indicator: none.
BLOOD GLUCOSE TESTING IN THE DIAGNOSIS AND
MONITORING OF TYPE 2 DIABETES (WSAS)
The question and answer sets below attempt to summarise the
content of the set of national guidance documents found, and
highlight any major differences. Overall, apart from differences
between the American Diabetes Association guidance of 1997,47
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reaffirmed in 20059 and 2006,48 and other consistent American
documents such as the Michigan50 and Veterans’ Affairs51
guidance, the other guidance documents found broadly agree,
although minor qualitative differences exist, mostly relating to
the specificity of the wording. Some guidance documents are
interrelated (for example in the UK, the PRODIGY, NICE and
UK Department of Health National Service Framework docu-
ments frequently cross-refer).
Who should I screen for diabetes?
We recommend an active (rather than opportunistic) screening,
which can be combined with screening of cardiovascular risk
in:
N Patients.65 years old.
N Patients .45 years old with one or more risk factors (box 1).
N Patients ,45 years old with two or more risk factors or
otherwise suspected to be at high risk.
N Repeating the test annually in those considered at high risk
to 3–5 yearly in those considered at low risk.
N For convenience the assessment should be incorporated into
protocols for interval cardiovascular risk assessment and
other active monitoring programmes.
N Active (rather than opportunistic) screening is considered
preferable by several guideline sources.
Absolute consensus on screening for diabetes does not exist.
The American Diabetes Association49 advocates considering
screening in all adults .45 years old (particularly those with
body mass index 25 or above and in younger patients with risk
factors). Population screening has however been reported as
not being cost effective,50 and other American guidance50 53
states that there is limited evidence to support mass population
screening of asymptomatic adults.
Most of the other national guidance documents54–61 specify
active but targeted approach to those with risk factors. The risk
factors quoted vary slightly between guidance documents; box
4 provides an overview of the at-risk groups listed in the various
guidelines.
The question of active versus opportunistic screening is
resource-dependent. The International Diabetes Federation
guideline62 refers to opportunistic screening of high risk people
only as a minimal care standard. A practical approach would be
to incorporate screening of people in the above groups into
protocols for other active screening systems (hypertension,
cardiovascular risk, well-woman) which would capture a
significant proportion of the target population and reduce the
resource implication for a separate active screening programme
were this to be used.
As the prevalence of risk factors is high in the general
Western populations over the age of 45 years, the practical
difference between targeted and population screening may not
be that great.
One guideline58 provides a pragmatic approach of screening
all those over 65 years old, those over 45 years old with one risk
factor, or those 18–45 years old with more than one risk factor.
A reasonable policy may therefore be to test all those over 65
years old, those over 45 years old with one or more of the above
risk factors, and those under 45 years old with two or more risk
factors or thought otherwise to be at particular risk (severe
hypertriglyceridaemia, gross obesity). Particular attention is
recommended for patients with multiple risk factors, as some
factors in isolation (such as age alone) may have a low yield.63
The guidelines are consistent in recommending annual
measurement for those considered at high risk of developing
diabetes and less frequently, eg 3 yearly, in those at low risk.
For practical purposes this test would combine easily with the
annual or 3–5 year cardiovascular risk assessment recommen-
dations. There is no clear distinction between high and low risk,
and in the absence of clear guidance we recommend that retest
intervals be decided prospectively with the patient on an
individual patient basis, based on the number and severity of
risk factors.
What test should I use?
We recommend:
N Measurement of random or preferably fasting plasma
glucose.
N Confirmation of a diagnostic result by a second, fasting,
plasma glucose test, unless the patient has unequivocal
symptoms of hyperglycaemia.
N Whole/capillary blood glucose meters are not recommended
for diagnosis—if used in screening they must be confirmed
by two plasma laboratory glucose measurements.
N Urine testing for diagnosis is not recommended.
Box 5 and table 2 (plasma values) show the diagnostic
criteria for impaired fasting glycaemia, impaired glucose
tolerance and diabetes.
There is good consensus among all of the guidance that the
diagnosis of diabetes requires two plasma measurements unless
unequivocal symptoms of hyperglycaemia are present.
Few guidance documents specifically refer to the type or
place of measurement.
However, with very few exceptions the guidance documents
refer to measurement of plasma glucose for diagnosis of
diabetes, which would implicitly indicate measurement on a
laboratory instrument rather than capillary blood glucose
meter, and the Singapore guideline60 refers specifically to
measurement in an accredited laboratory as the preferred
method. The Flemish guideline58 specifically refers to meters
not being recommended for screening, and the International
Diabetes Federation guideline63 includes capillary blood glucose
as an option (although fasting laboratory glucose is preferred)
in its minimal care scenario. Urine testing is not recommended
for diagnosis unless blood glucose measurement is not
available.
While capillary measurements are convenient to perform in
local surgeries by point of care testing, the potential confusion
that may arise between diagnostic criteria for plasma and
whole venous or capillary blood results combined with the
quality control and audit trail of results held by analytical
laboratories provide a strong argument for formal laboratory
analysis to make the diagnosis of diabetes. We would therefore
recommend that if a point of care testing (POCT) blood glucose
meter is used in initial screening, a diagnostic POCT result
should be confirmed by one (if unequivocal symptoms are
present) or two formal laboratory plasma glucose measure-
ments.
There is consensus as to the thresholds which define
diabetes, based on WHO criteria,64 but there are different
approaches to the ‘‘pre-diabetes’’ states and the type of
diagnostic plasma glucose test to use.
Most guidance advocate a fasting plasma glucose or OGTT as
the confirmatory test preceded by either a random or fasting
measurement. The ADA in 1997 adopted FPG as the preferred
test,47 and confirmed this in the most recent subsequent
position statement.48
None of the guidelines currently recommend use of HbA1c in
the diagnosis of diabetes.
When should I perform an oral glucose tolerance test
(OGTT)?
We recommend:
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– Oral glucose tolerance testing may be helpful in patients in
whom a fasting result is non-diagnostic (5.6–6.9 mmol/l),
but either
– diabetes is strongly suspected on clinical or laboratory
grounds from risk factors for diabetes; or
– impaired glucose tolerance is suspected in a patient
without impaired fasting blood (5.6 . plasma glucose ,
6.1 mmol/l) from risk factors for diabetes.
N Systematic use of OGTT in all patients with impaired fasting
glucose (IFG) poses considerable logistic difficulties and
would be of uncertain benefit in light of the annual testing
recommendations in at-risk patients.
Guidance on the use of the 75 g OGTT varies. While all offer
OGTT as a means of diagnosing diabetes, there is little clear
guidance about when it should be used. The American Diabetes
Association recommendation for measurement of fasting
glucose alone, created two separate categories of impaired
glucose metabolism, impaired fasting glucose and impaired
glucose tolerance. More end-point data are available on the
latter although both appear to be associated with increased risk
of developing diabetes and adverse cardiovascular outcome.65–69
However many people without IFG have impaired glucose
tolerance (IGT) and vice versa.70–73 While simpler to perform
than a glucose load, a fasting plasma glucose measurement diag-
nostic of IFG will fail to identify a significant number of people
with IGT who are at risk of diabetes and cardiovascular disease.
The upper limit for fasting plasma glucose of 6.1 mmol/l
therefore appears to miss a proportion of patients with IGT. The
2005 American Diabetes Association follow-up report defined
IFG as plasma glucose .5.6 mmol/l, and the International
Diabetes Federation recommends OGTT if the measured plasma
glucose is 5.6–7.0 mmol/l. Whilst the current UK guidance cites
an upper limit of 6.1 for fasting plasma glucose,56 consistent
with earlier American guidance, it would appear reasonable to
consider OGTT to detect impaired glucose tolerance in patients
with plasma fasting glucose below 6.1 but above 5.6 mmol/and
clinically suspected of having IGT because of clinical risk factors
or other laboratory results (eg hypertriglyceridaemia). The
benefit of systematic OGTT in all those with fasting plasma
glucose .5.6 mmol/l is unclear in light of the logistic burden
this would impose. Several of the guideline documents
acknowledge the logistic and cost difficulties surrounding
widespread use of the OGTT. In addition, despite the OGTT,
being a defining tool for diagnosis is itself poorly reproducible
over time, particularly in the ‘‘pre-diabetes’’ phase and ‘‘early’’
stage of diabetes.74 This difficulty is partly circumvented by the
consensus emerging from the guidelines that an annual test be
performed in high risk people and in those with IGT or IFG,
compared to 3-yearly in patients over 45 years old at lower risk
The question of how frequently to retest patients over 65
years old is not addressed, and it would seem reasonable to
recommend annual testing in patients with IFG or IGT, as in
younger patients, and in those with normal fasting plasma
glucose but any additional risk factors.
When should I measure blood glucose in a diabetic
patient?
We recommend:
N ‘‘Routine’’ glucose measurement in a primary care clinic
setting is of limited if any value.
N Measurement to confirm suspected hypoglycaemia or
hyperglycaemia in unwell patients.
N Intermittent (eg, annual) measurement, either via a labora-
tory plasma glucose or clinic POCT capillary glucose to
validate patient and meter technical results in patients using
self-monitoring of blood glucose concentrations (SMBG), or
if incorrect meter results are suspected.
Box 4: Prevalent risk factors for type 2 diabetes
N Hypertension
N Family history in first degree relative
N Overweight (body mass index .25 kg/m2) or girth
.88 cm (women) or 102 cm (men)
N Vascular disease
N Hyperlipidaemia, notably low HDL (,0.9 mmol/l) or
raised triglycerides (.2.3 mmol/l)
N Recognised higher risk ethnic groups, eg Asian origin
N Polycystic ovarian syndrome
N Previous gestational diabetes or large baby (.4 kg)
N Drugs known to be diabetogenic (for example, corticos-
teroids, or atypical anti-psychotics, eg clozapine)
N Drugs known to be diabetogenic (for example, corticos-
teroids, atypical anti-psychotics, eg clozapine, or b
blockers)
N Other autoimmune disease, eg thyroid disease, perni-
cious anaemia
Box 5: Diagnosis of diabetes mellitus (from
Canadian diabetes Association54)
N FPG >7.0 mmol/l
Fasting = no caloric intake for at least 8 hours
N Casual PG >11.1 mmol/l + symptoms of diabetes
Casual = any time of the day, without regard to the interval
since the last meal
Classic symptoms of diabetes = polyuria, polydipsia and
unexplained weight loss
N 2hPG in a 75-g OGTT >11.1 mmol/l
A confirmatory laboratory glucose test (an FPG, casual PG, or
a 2hPG in a 75 g OGTT) must be done in all cases on another
day in the absence of unequivocal hyperglycaemia accom-
panied by acute metabolic decompensation.
PG, plasma glucose; 2hPG, 2-hour plasma glucose; FPG,
fasting plasma glucose; OGTT, oral glucose tolerance test.
Table 2 Diagnostic plasma glucose levels for the diagnosis
of IFG, IGT and diabetes mellitus (from Engelau et al52)
FPG (mmol/l)
2hPG in a 75 g OGTT
(mmol/l)
IFG 6.1–6.9 NA
IFG (isolated) 6.1–6.9 and ,7.8
IGT (isolated) ,6.1 and 7.8–11.0
IFG and IGT 6.1–6.9 and 7.8–11.0
Diabetes >7.0 or >11.1
2hPG, 2-hour plasma glucose; FPG, fasting plasma glucose; IFG, impaired
fasting glucose; IGT, impaired glucose tolerance; NA, not applicable;
OGTT, oral glucose tolerance test; PG, plasma glucose.
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The guidance documents found do not recommend routine
blood glucose measurement in diabetic patients other than in
situations in which a clear clinical indication exists, notably in
patients who are unwell, in order to detect or confirm suspected
hyperglycaemia or hypoglycaemia.
One guideline specifically advocates comparison with a
paired laboratory glucose sample75 to check technical perfor-
mance, or if meter records are inconsistent with other (clinical
or laboratory) indicators of glycaemic control. Others are less
specific in their guidance, but recommending intermittent
evaluation of patient meter use appears consistently in the differ-
ent guidelines. There appears to be limited evidence at present to
support any particular strategy to monitor patient meter use.
Which patients should perform SMBG?
We recommend SMBG in:
N Patients being treated with insulin or preparing to start
insulin.
N Patients on oral treatments in conjunction with an inte-
grated educational programme to identify glucose excursions
due to lifestyle changes or intercurrent illness.
N Patients who are intensifying glycaemic control for medical
reasons, eg complications.
N Patients in whom HbA1c results are thought to be clinically
inconsistent with the patient’s state.
However:
N The value of SMBG in well controlled, well motivated
patients with stable HbA1c is uncertain.
N SMBG use and frequency should be tailored to its specific
purpose, and the utility and frequency of SMBG in individual
patients should be assessed regularly (eg annually).
There is good consensus that SMBG is required in type 1 or 2
patients receiving insulin, and this will not be further discussed.
In patients with type 2 diabetes managed on diet or oral
hypoglycaemic agents, SMBG is considered helpful and is
associated with lower HbA1c when used as part of a structured
diabetes educational programme but not as a stand-alone
intervention.48 60 It would appear logical to tailor the frequency
and use of self-monitoring to individual patients depending on
need and purpose. There would appear to be questionable merit
in the systematic use of SMBG in well-controlled stable diabetic
patients with a good understanding of their diabetes management
and consistently low HbA1c, except during intercurrent illness.
GMS contract indicator: none relating to these specific
questions.
CONCLUSION
This tenth review brings us to a running total of approximately
113 question and answer sets written in order to provide an
overview of current advice in use of laboratory tests in primary
care. Answers to the first nine question–answer sets can be
found elsewhere.76–84 They have all used a common search
methodology,85 although where recent systematic reviews have
been performed, the guidance relies heavily also on the findings
of these reviews. For authors wishing to consult the UK General
Medical Services Contract and related Quality and Outcomes
Framework, these can be found elsewhere.86–88
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